Granulomatous Dermatitis in a Patient With Cholangiocarcinoma Treated With BRAF and MEK Inhibitors.
作者信息
Bormann Jordan L, Kerkvliet Amy M
机构信息
Dr. Bormann is from the University of Utah Health Dermatology, Salt Lake City. Dr. Kerkvliet is from the Department of Pathology, Sanford School of Medicine, University of South Dakota, Sioux Falls.
出版信息
Cutis. 2023 Sep;112(3):E17-E20. doi: 10.12788/cutis.0859.
PMID:37903392
Abstract
摘要
相似文献
1
Granulomatous Dermatitis in a Patient With Cholangiocarcinoma Treated With BRAF and MEK Inhibitors.一名接受BRAF和MEK抑制剂治疗的胆管癌患者发生的肉芽肿性皮炎
Cutis. 2023 Sep;112(3):E17-E20. doi: 10.12788/cutis.0859.
2
BRAF and MEK inhibitor-associated optic neuropathy in stage IIIC BRAF+ melanoma.BRAF基因和丝裂原活化蛋白激酶激酶（MEK）抑制剂相关的视神经病变在IIIC期BRAF基因阳性黑色素瘤中的情况
Can J Ophthalmol. 2023 Dec;58(6):e251-e253. doi: 10.1016/j.jcjo.2023.07.008. Epub 2023 Aug 3.
3
[Subretinal fluid associated with MEK and BRAF inhibitors].[与MEK和BRAF抑制剂相关的视网膜下液]
J Fr Ophtalmol. 2022 Nov;45(9):1091-1092. doi: 10.1016/j.jfo.2022.05.007. Epub 2022 Jul 28.
4
Macrophage activation syndrome associated with BRAF and MEK inhibitors during adjuvant treatment of melanoma.黑色素瘤辅助治疗期间与BRAF和MEK抑制剂相关的巨噬细胞活化综合征
J Eur Acad Dermatol Venereol. 2022 Sep;36(9):e688-e689. doi: 10.1111/jdv.18130. Epub 2022 May 3.
5
Panniculitis in patients treated with BRAF/MEK inhibitors: Presentation of 4 new cases.接受BRAF/MEK抑制剂治疗的患者发生的脂膜炎：4例新病例报告
Med Clin (Barc). 2022 Jun 10;158(11):e8-e9. doi: 10.1016/j.medcli.2021.10.017. Epub 2022 Jan 4.
6
Permanent dose reduction due to adverse reactions does not decrease efficacy of BRAF/MEK inhibition in metastatic melanoma.因不良反应导致的永久性剂量减少不会降低BRAF/MEK抑制在转移性黑色素瘤中的疗效。
J Eur Acad Dermatol Venereol. 2023 May;37(5):e605-e607. doi: 10.1111/jdv.18871. Epub 2023 Jan 25.
7
What impact will BRAF/MEK-inhibitors have on the melanoma treatment armamentarium and are there challenges ahead?BRAF/MEK抑制剂对黑色素瘤治疗手段会产生何种影响，未来是否存在挑战？
Expert Opin Pharmacother. 2023 May-Aug;24(10):1101-1103. doi: 10.1080/14656566.2023.2211765. Epub 2023 May 8.
8
Potential drug-drug interactions with mitogen-activated protein kinase (MEK) inhibitors used to treat melanoma.用于治疗黑色素瘤的丝裂原活化蛋白激酶 (MEK) 抑制剂的潜在药物相互作用。
Expert Opin Drug Metab Toxicol. 2023 Jul-Dec;19(8):555-567. doi: 10.1080/17425255.2023.2255519. Epub 2023 Sep 6.
9
[Ocular toxicity of targeted therapies with MEK inhibitors and BRAF inhibitors in the treatment of metastatic cutaneous melanoma].[MEK抑制剂和BRAF抑制剂靶向治疗转移性皮肤黑色素瘤的眼部毒性]
J Fr Ophtalmol. 2022 Jun;45(6):612-618. doi: 10.1016/j.jfo.2021.08.005. Epub 2022 Apr 29.
10
Severe colitis in patients with melanoma treated with BRAF/MEK inhibitors.BRAF/MEK 抑制剂治疗的黑色素瘤患者出现严重结肠炎。
Aliment Pharmacol Ther. 2023 Apr;57(7):792-799. doi: 10.1111/apt.17352. Epub 2022 Dec 28.
Zotero 插件